Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy

Blood 2026

View at publisher
Authors: Susan Bal, Gayathri Ravi, Binod Dhakal, Natalie S Callander, Eva Medvedova, Bhagirathbhai Dholaria, Smith Giri, Kelly Godby, Rebecca Silbermann, Fady M. Mikhail, Forest Huls, Vishnu Reddy
+1 more Luciano J. Costa
DOI: 10.1182/blood.2025031952
Cited by: 2
References: 18

Abstract

ABSTRACT: Quadruplet (QUAD) induction and autologous stem cell transplantation (ASCT) leads to high rates of measurable residual disease (MRD) negativity with improved outcomes in multiple myeloma (MM). The t(11;14) confers unique biology and different kinetics of treatment response. We analyzed MRD trajectories of patients treated with QUAD/ASCT and MRD-adapted post-ASCT management. Of the 302 patients assessed, 47 (16%) had t(11;14)+ MM. Median follow-up was 45.8 months. MRD negativity at

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Cancer Treatment and Pharmacology Protein Degradation and Inhibitors

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
16
Pages
1857–1862
Publication date
27 January 2026
Language
EN